1095 related articles for article (PubMed ID: 17707430)
1. The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children.
Franco I; Landau-Dyer L; Isom-Batz G; Collett T; Reda EF
J Urol; 2007 Oct; 178(4 Pt 2):1775-9; discussion 1779-80. PubMed ID: 17707430
[TBL] [Abstract][Full Text] [Related]
2. Botulinum A toxin urethral sphincter injection in children with nonneurogenic neurogenic bladder.
Mokhless I; Gaafar S; Fouda K; Shafik M; Assem A
J Urol; 2006 Oct; 176(4 Pt 2):1767-70; discussion 1770. PubMed ID: 16945643
[TBL] [Abstract][Full Text] [Related]
3. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.
Smith CP; Nishiguchi J; O'Leary M; Yoshimura N; Chancellor MB
Urology; 2005 Jan; 65(1):37-41. PubMed ID: 15667859
[TBL] [Abstract][Full Text] [Related]
4. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
Schmid DM; Sauermann P; Werner M; Schuessler B; Blick N; Muentener M; Strebel RT; Perucchini D; Scheiner D; Schaer G; John H; Reitz A; Hauri D; Schurch B
J Urol; 2006 Jul; 176(1):177-85. PubMed ID: 16753396
[TBL] [Abstract][Full Text] [Related]
5. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents.
Kuo HC
Urology; 2004 May; 63(5):868-72. PubMed ID: 15134967
[TBL] [Abstract][Full Text] [Related]
6. Changing concepts concerning the management of vesicoureteral reflux.
Herndon CD; DeCambre M; McKenna PH
J Urol; 2001 Oct; 166(4):1439-43. PubMed ID: 11547107
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type A in combination with standard urotherapy for children with dysfunctional voiding.
Petronijevic V; Lazovic M; Vlajkovic M; Slavkovic A; Golubovic E; Miljkovic P
J Urol; 2007 Dec; 178(6):2599-602; discussion 2602-3. PubMed ID: 17945299
[TBL] [Abstract][Full Text] [Related]
8. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics.
Kuo HC
Urology; 2005 Jul; 66(1):94-8. PubMed ID: 15992869
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and durability of botulinum-A toxin for refractory dysfunctional voiding in children.
Vricella GJ; Campigotto M; Coplen DE; Traxel EJ; Austin PF
J Urol; 2014 May; 191(5 Suppl):1586-91. PubMed ID: 24679879
[TBL] [Abstract][Full Text] [Related]
10. The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor.
Hoebeke P; De Caestecker K; Vande Walle J; Dehoorne J; Raes A; Verleyen P; Van Laecke E
J Urol; 2006 Jul; 176(1):328-30; discussion 330-1. PubMed ID: 16753434
[TBL] [Abstract][Full Text] [Related]
11. Dysfunctional voiding in women.
Carlson KV; Rome S; Nitti VW
J Urol; 2001 Jan; 165(1):143-7; discussion 147-8. PubMed ID: 11125384
[TBL] [Abstract][Full Text] [Related]
12. Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity.
Schulte-Baukloh H; Knispel HH; Stolze T; Weiss C; Michael T; Miller K
Urology; 2005 Oct; 66(4):865-70; discussion 870. PubMed ID: 16230156
[TBL] [Abstract][Full Text] [Related]
13. Is it reasonable to treat refractory voiding dysfunction in children with botulinum-A toxin?
Radojicic ZI; Perovic SV; Milic NM
J Urol; 2006 Jul; 176(1):332-6; discussion 336. PubMed ID: 16753436
[TBL] [Abstract][Full Text] [Related]
14. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients.
Mascarenhas F; Cocuzza M; Gomes CM; Leão N
Neurourol Urodyn; 2008; 27(4):311-4. PubMed ID: 17914742
[TBL] [Abstract][Full Text] [Related]
15. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity.
Karsenty G; Reitz A; Lindemann G; Boy S; Schurch B
Urology; 2006 Dec; 68(6):1193-7. PubMed ID: 17141831
[TBL] [Abstract][Full Text] [Related]
16. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction.
Schulte-Baukloh H; Weiss C; Stolze T; Stürzebecher B; Knispel HH
Urology; 2005 Jul; 66(1):82-7. PubMed ID: 15992872
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
[TBL] [Abstract][Full Text] [Related]
18. Breaking the vicious circle: Onabotulinum toxin A in children with therapy-refractory dysfunctional voiding.
't Hoen LA; van den Hoek J; Wolffenbuttel KP; van der Toorn F; Scheepe JR
J Pediatr Urol; 2015 Jun; 11(3):119.e1-6. PubMed ID: 25794865
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux.
Karsenty G; Elzayat E; Delapparent T; St-Denis B; Lemieux MC; Corcos J
J Urol; 2007 Mar; 177(3):1011-4. PubMed ID: 17296399
[TBL] [Abstract][Full Text] [Related]
20. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction.
Kuo HC
J Urol; 2003 Nov; 170(5):1908-12. PubMed ID: 14532805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
